Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.41 |
| ▸ | CDC42BPB | Q9Y5S2 | 4/20 | 0.41 |
| ▸ | BPTF | Q12830 | 2/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 4/20 | 0.36 |
| ▸ | ATAD2 | Q6PL18 | 4/20 | 0.36 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 2/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4935343 | 1.00 | ROCK2 (0.41) | ROCK2ROCK1CDC42BPBBPTFCSF1R | |
| SCHEMBL4937428 | 0.93 | ROCK2 (0.42) | ROCK2ROCK1CDC42BPBBRD4ATAD2 | |
| SCHEMBL4931029 | 0.85 | ADORA2A (0.39) | — | |
| SCHEMBL5963533 | 0.83 | POLB (0.36) | ROCK2ROCK1CDC42BPBCSF1RPDE5A | |
| SCHEMBL4951394 | 0.82 | LRRK2 (0.39) | — | |
| SCHEMBL4951836 | 0.80 | GRM1 (0.33) | — | |
| SCHEMBL4954967 | 0.80 | PDE1B (0.42) | BRD4MKNK1MKNK2 | |
| SCHEMBL4952368 | 0.80 | PDE1B (0.42) | BRD4MKNK1MKNK2 | |
| SCHEMBL4933819 | 0.78 | POLB (0.41) | — | |
| SCHEMBL4951407 | 0.78 | MAPT (0.44) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275078-A1 | Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | ROCK2 330/4885ROCK1 141/4885CDC42BPB 374/4885 |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | PDE4B, PDE3B, PDE4A | ROCK2 397/4885ROCK1 195/4885CDC42BPB 1208/4885 |
| US-20080275078-A1 | Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors | PDE4B, PDE3B, PDE4A | ROCK2 68/4885ROCK1 98/4885CDC42BPB 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.